CB2receptor‐mediated migration of immune cells: it can go either way
Open Access
- 29 January 2008
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 153 (2) , 299-308
- https://doi.org/10.1038/sj.bjp.0707523
Abstract
Though many studies have examined the role of CB2receptors in immune cell migration, it has been difficult to form definitive conclusions about the physiopathological role of these receptors in regulating immune responses and how this might be pharmacologically targeted for therapy. Do cannabinoids promote inflammation through the recruitment of immune cells, or reduce inflammation by interfering with the action of other chemoattractants? Is therapeutic intervention with an agonist or antagonist more appropriate for the reduction of inflammation? In this review, we will summarize the progress that has been made in answering these questions and outline current hypotheses.British Journal of Pharmacology(2008)153, 299–308; doi:10.1038/sj.bjp.0707523; published online 5 November 2007Keywords
This publication has 85 references indexed in Scilit:
- μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesisBritish Journal of Pharmacology, 2006
- Effects of Peripheral Cannabinoid Receptor Ligands on Motility and Polarization in Neutrophil-like HL60 Cells and Human NeutrophilsJournal of Biological Chemistry, 2006
- Anandamide inhibits adhesion and migration of breast cancer cellsExperimental Cell Research, 2006
- Agonist-Directed Trafficking of Response by Endocannabinoids Acting at CB2 ReceptorsThe Journal of Pharmacology and Experimental Therapeutics, 2005
- The challenge of brain lipidomicsProstaglandins & Other Lipid Mediators, 2004
- The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent mannerBlood, 2004
- Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 PathwayCancer Research, 2004
- SR141716A, a potent and selective antagonist of the brain cannabinoid receptorPublished by Wiley ,2001
- Opiates Transdeactivate Chemokine Receptors: δ and μ Opiate Receptor–mediated Heterologous DesensitizationThe Journal of Experimental Medicine, 1998
- Cannabinol Derivatives: Binding to Cannabinoid Receptors and Inhibition of AdenylylcyclaseJournal of Medicinal Chemistry, 1997